Arcticzymes Technologies ASA
OSE:AZT
Arcticzymes Technologies ASA
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
Revenue Growth: Sales rose 24% year-on-year to NOK 28.5 million in Q3, with overall revenues just shy of NOK 30 million for the quarter.
Profitability: EBITDA improved sharply, reaching NOK 3.5 million in Q3 compared to a negative NOK 2.3 million last year, with a 12% EBITDA margin.
Molecular Tools Recovery: Molecular tools segment returned to growth, up 45% year-on-year in Q3, mainly due to a key account returning and broader customer gains.
Brenntag Partnership: ArcticZymes signed an exclusive European distribution deal with Brenntag for nucleases, expected to fuel long-term growth and expand market reach.
Biomanufacturing Strength: Biomanufacturing sales grew, with GMP nucleases now making up 26% of segment sales and ArcticZymes supplying 9 of the top 10 CDMOs in advanced therapies.
Cash Position: Cash balance stands at nearly NOK 260 million, with net cash up NOK 14 million in the first 9 months, supporting future growth initiatives.
Strategic Focus: Management highlighted expansion into metagenomics and RNA markets, ongoing channel development, and evaluation of inorganic growth opportunities.
